Dr. O'Brien is a seasoned biotech executive with expertise in oncology research and development and corporate strategy. He has directed multiple oncology therapeutics programs from preclinical R&D to Proof-of-Concept Phase II studies. Dr. O′Brien has more than 20 years of diverse experience in the drug discovery and development arena a
Dr. O'Brien is a seasoned biotech executive with expertise in oncology research and development and corporate strategy. He has directed multiple oncology therapeutics programs from preclinical R&D to Proof-of-Concept Phase II studies. Dr. O′Brien has more than 20 years of diverse experience in the drug discovery and development arena and, as an entrepreneur, he has been co-founder of several biotech companies.
Dr. Thiele brings a wealth of experience to Sisu as an academic and biotech researcher and as a thought leader in the field of Heat Shock Transcription Factors for over three decades. Dr. Thiele’s expertise encompasses the structural and chemical biology of HSF1 and the function and regulation of HSF1 in multiple cellular and animal models of disease.
Dr. Huang serves as the Chairman of Sisu's Scientific Advisory Board. His current position is Professor and Chair, Department of Pathology at the Duke University School of Medicine. Dr. Huang is an internationally renowned surgical pathologist and prostate cancer researcher. His clinical expertise is in the pathologic diagnosis of geni
Dr. Huang serves as the Chairman of Sisu's Scientific Advisory Board. His current position is Professor and Chair, Department of Pathology at the Duke University School of Medicine. Dr. Huang is an internationally renowned surgical pathologist and prostate cancer researcher. His clinical expertise is in the pathologic diagnosis of genitourinary tumors and his research laboratory investigates the molecular mechanisms, biomarkers and novel therapies for advanced prostate cancer.